|
AUA Guidelines on Early Detection of Prostate Cancer: Maximizing Benefits, Minimizing Harm Webcast (2025) |
|
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Non-Physician Participation
|
|
$0.00 |
Prostate cancer detection remains one of the most common and most controversial aspects of urologic practice. In addition to the complexities around screening and use of PSA, the role of other biomarkers, biopsy techniques such as transperineal biopsy, and MRI for targeted biopsy are evolving rapidly. This course is intended for urologists, advanced practice providers, and trainees interested in using the most evidence-based methods for optimizing detection of clinically important prostate cancers, while improving patient experience and minimizing complications. |
|
Incorporating Genomic Testing and Advanced Imaging for Prostate Cancer Into Your Practice Webcast (2025) |
|
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Non-Physician Participation
|
|
$0.00 |
There are multiple genomic tests and advanced imaging modalities (MRI, PSMA PET, etc) currently available for men to detect and risk stratify prostate cancer. The outcomes of these tests may lead to different detection strategies (observation, immediate biopsy, etc) and treatment decisions (active surveillance, surgery, radiation, adjuvant therapy, etc). We will also discuss germline testing as inherited mutations have considerable implications for screening, treatment, genetic counseling, and cascade testing of family members. |
|
AUA Advanced Prostate Cancer Course Webcast (2025) |
|
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Non-Physician Participation
|
|
$0.00 |
This course will be focused on comprehensive AUA/SUO Guidelines on APC in the management and outcomes of men with biochemical recurrence, locally advanced, metastatic HSPC and CRPC. The course will include risk stratification, germline testing, PET imaging, the use of ADT in combination with novel androgen axis therapy and chemotherapy in men with newly diagnosed advanced and mHSPC. Early treatment intensification and evidenced based guidelines will be covered. The course will also cover non-metastatic CRPC, and treatment for mCRPC. |
|
Non-Muscle Invasive Bladder Cancer Treatment Dilemmas: The Cases You Face and How Best to Treat Them Webcast (2025) |
|
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Non-Physician Participation
|
|
$0.00 |
The course will highlight recent updates to AUA, European Association of Urology, and National Comprehensive Cancer Network Guidelines in the rapidly evolving field of bladder cancer before working through challenging but common case scenarios that will outline important changes as well as concepts essential in providing evidence-based care.ACKNOWLEDGEMENTS:This educational activity is supported by an independent educational grants from:Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. |
|
Management of Non-Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems Webcast (2025) |
|
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Non-Physician Participation
|
|
$0.00 |
This course will focus on specific topics discussed in the recent/amended AUA practice guidelines for non muscle-invasive bladder cancer (NMIBC) and detail strategies to manage common clinical predicaments involved in the management of these tumors. The course will include short didactic lectures by each of the faculty but will focus predominantly on case presentations highlighting common and often perplexing topics in NMIBC. |
|
Integration of Biomarkers, MRI and PSMA PET Imaging Into the Management of Prostate Cancer Webcast (2025) |
|
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Non-Physician Participation
|
|
$0.00 |
|
|
The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion Webcast (2025) |
|
- 4.00 AMA PRA Category 1 Credit™
- 4.00 Non-Physician Participation
|
|
$0.00 |
This comprehensive, interactive course equips urologic professionals with the knowledge and skills needed to effectively manage patients with advanced prostate cancer. Through an in-depth exploration of guidelines, treatment modalities, and emerging therapies, participants will gain a thorough understanding of this complex disease and its evolving landscape. ACKNOWLEDGEMENTS:This educational activity is supported by independent educational grants from: |
|
Highlights from AUA2025: Advances in NMIBC (2025) |
|
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Non-Physician Participation
|
|
$0.00 |
Highlights from AUA2025: Advances in NMIBC will discuss the best in the latest advancements in Non-Muscle Invasive Bladder Cancer (NMIBC) from the AUA Annual Meeting! |
|
The Surgical Management of BPH and Updates from the AUA Clinical Guidelines Webcast (2025) |
|
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Non-Physician Participation
|
|
$0.00 |
As a direct result of the evolving technologies and procedures related to the surgical management of BPH, urologists must continue increasing their knowledge and skills of the various treatment options available. |
|
The Surgical Management of BPH and Updates from the AUA Clinical Guidelines Podcast (2025) |
|
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Non-Physician Participation
|
|
$0.00 |
As a direct result of the evolving technologies and procedures related to the surgical management of BPH, urologists must continue increasing their knowledge and skills of the various treatment options available. |
|
The Latest Breakthroughs in LG-IR-NMIBC (2025) Webcast/Podcast |
|
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Non-Physician Participation
|
|
$0.00 |
|
|
The Latest Breakthroughs in mHSPC (2025) Webcast/Podcast |
|
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Non-Physician Participation
|
|
$0.00 |
In response to critical insights from the American Urological Association's (AUA) Advanced Prostate Cancer Global Needs Assessment, the AUA proud to present The Latest Breakthroughs in Metastatic Hormone Sensitive Prostate Cancer (mHSPC). |
|
Advanced Prostate Cancer Clinical Trial Research Webinar Series (2025) |
|
|
11/11/2025 |
$0.00 |
This webinar series was developed in support of the objectives of the AUA Clinical Trials Collective™. Prostate cancer is the second leading cause of cancer death in men in the United States. Through clinical research advanc |
|
Global Perspectives in Urothelial Carcinoma (2025) – LATAM Focus Portuguese Webcast |
|
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Non-Physician Participation
|
|
$0.00 |
|
|
Global Perspectives in Urothelial Carcinoma (2025) – LATAM Focus Spanish Webcast |
|
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Non-Physician Participation
|
|
$0.00 |
|
Facebook
X
LinkedIn
Forward